MIND Matters is a quarterly publication that aims to keep the community abreast of developments in research and happenings across the Institute| UCI MIND
Welcome to UCI MINDcast, UCI MIND’s new video and podcast library with up-to-date content on the latest in Alzheimer’s and dementia research, education and care!| UCI MIND
Today, the FDA convened its Peripheral and Central Nervous System Drugs Advisory Committee to review the data from pivotal clinical trials of donanemab, a monoclonal antibody against the beta amyloid protein that accumulates in the brain of people with Alzheimer’s disease. One of these trials was conducted at UCI MIND. The efficacy of donanemab in treating early Alzheimer’s disease in people with Mild Cognitive Impairment and mild dementia due to Alzheimer’s disease is largely agreed to...| UCI MIND